Hepatocellular Carcinoma

Donafenib conferred a modest but statistically significant OS improvement as first-line therapy for advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Hepatitis C virus infection remains a strong driver of hepatocellular carcinoma with a high rate of progression to cirrhosis over an extended follow-up period, according to a study in International Journal of Molecular Sciences.

Hepatocellular carcinoma is the most common type of liver cancer worldwide. Individuals who have been diagnosed with hepatitis B, hepatitis C or cirrhosis have the highest risk for developing HCC. While the incidence rate decreased among younger and middle-aged adults between 1992 and 2015, the overall incidence rate of HCC in the United States increased from 4.1 cases per 100,000 people in 1992 to 9.5 in 2015.

Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study published in The New England Journal of Medicine.

The FDA granted orphan drug designation to MIV-818 for the treatment of hepatocellular carcinoma.

For patients with nonalcoholic fatty liver disease, a positive anti-hepatitis B core antibody was correlated with cirrhosis and hepatocellular carcinoma, according to a study published in the American Journal of Gastroenterology.

Primary liver cancer rates continue to increase in many regions of the world despite extensive efforts to prevent the disease, according to study results published in Cancer.

Low-dose aspirin use appeared associated with significantly lower risk for hepatocellular carcinoma and lower liver-related mortality among patients with chronic viral hepatitis, according to results of a retrospective study published in The New England Journal of Medicine.

The FDA granted accelerated approval to nivolumab plus ipilimumab for treatment of patients with hepatocellular carcinoma who previously received sorafenib.